- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Patent holdings for IPC class A61P 9/10
Total number of patents in this class: 9373
10-year publication summary
|
348
|
452
|
617
|
546
|
672
|
728
|
603
|
565
|
593
|
429
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Daiichi Sankyo Company, Limited | 1889 |
113 |
| The Regents of the University of California | 20868 |
78 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3325 |
71 |
| Osaka University | 3258 |
58 |
| Shionogi & Co., Ltd. | 885 |
55 |
| Sunshine Lake Pharma Co., Ltd. | 630 |
54 |
| Takeda Pharmaceutical Company Limited | 2698 |
51 |
| Novartis AG | 10174 |
49 |
| Bristol-myers Squibb Company | 4757 |
48 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 876 |
46 |
| Amarin Pharmaceuticals Ireland Limited | 271 |
45 |
| Bayer Pharma AG | 1009 |
38 |
| Mitsubishi Tanabe Pharma Corporation | 394 |
36 |
| Kowa Company, Ltd. | 1244 |
35 |
| University of Pittsburgh - Of the Commonwealth System of Higher Education | 3339 |
35 |
| China Pharmaceutical University | 364 |
33 |
| Centre National de La Recherche Scientifique | 11092 |
32 |
| Institut National de La Sante et de La Recherche Medicale (inserm) | 3295 |
32 |
| The Johns Hopkins University | 5929 |
31 |
| The Brigham and Women's Hospital, Inc. | 2296 |
31 |
| Other owners | 8402 |